Gamida Cell
Gamida Cell develops allogeneic cell therapy products using proprietary nicotinamide (NAM) technology to enhance and expand cells. These therapeutics are designed to treat patients with malignant and non-malignant hematological conditions, as well as non-hematological diseases. The company focuses on cell and immune therapy research, development, and manufacturing for the transplantation market.
Biotechnology
Healthcare
Cell Therapy
Oncology
Funding summary
- Total raised
- €85.7M
- Funding rounds
- 7
Investors in Gamida Cell
Investors on record for Gamida Cell. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Gamida Cell?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors